title: Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin.
abstract: We investigated the genotype-dependent therapeutic potential of targeting the phosphoinositide 3-kinase (PI3K)/Akt pathway for thyroid cancer. Proliferation of TPC1, Hth7, FTC133, OCUT1, K1, and BCPAP cells that harbored PI3K/Akt-activating genetic alterations was potently inhibited by the Akt inhibitor perifosine, whereas SW1736, Hth74, WRO, KAT18, and TAD2 cells that harbored no genetic alterations had no or only modest responses. Inhibition of Akt phosphorylation by perifosine was seen in these cells. Genetic-dependent apoptosis was induced by perifosine in cells selectively tested. Similarly, potent inhibition of cell proliferation by the mammalian target of rapamycin (mTOR) inhibitor temsirolimus occurred in virtually all the cells harboring genetic alterations, whereas modest inhibition was seen in some of the cells not harboring genetic alterations. Temsirolimus inhibited the phosphorylation of p70S6K, a substrate of mTOR. Knockdown of Akt1/2 or mTOR by shRNA approach inhibited the proliferation and colony formation of FTC133 and OCUT1 cells that harbored genetic alterations in the PI3K/Akt pathway but had no effect on SW1736 and KAT18 cells that did not. Transfection with PIK3CA mutants greatly sensitized SW1736 cells to perifosine and temsirolimus. Growth of xenograft tumors derived from FTC133 cells but not SW1736 cells in nude mice was dramatically inhibited by perifosine. Thus, this work for the first time shows that genetic alterations in the PI3K/Akt pathway confer thyroid cancer cells addiction to this pathway and their sensitivity to inhibition by targeting Akt and mTOR. This genotype-based targeting of the PI3K/Akt pathway using Akt and mTOR inhibitors may offer an effective therapeutic strategy for thyroid cancer and warrants further studies.
authors.affiliation: Division of Endocrinology and Metabolism, Johns Hopkins University School of Medicine, Baltimore, Maryland 21287, USA.
authors.forename: Dingxie
authors.initials: D
authors.lastname: Liu
authors.forename: Peng
authors.initials: P
authors.lastname: Hou
authors.forename: Zhi
authors.initials: Z
authors.lastname: Liu
authors.forename: Guojun
authors.initials: G
authors.lastname: Wu
authors.forename: Mingzhao
authors.initials: M
authors.lastname: Xing
mesh_terms: D000818:Animals; D048708:Cell Growth Processes / Q000187:drug effects; D045744:Cell Line, Tumor; D058534:Class I Phosphatidylinositol 3-Kinases; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D051058:Oncogene Protein v-akt / Q000037:antagonists & inhibitors / Q000235:genetics* / Q000378:metabolism; D019869:Phosphatidylinositol 3-Kinases / Q000096:biosynthesis / Q000235:genetics* / Q000378:metabolism; D000081082:Phosphoinositide-3 Kinase Inhibitors; D010767:Phosphorylcholine / Q000031:analogs & derivatives* / Q000494:pharmacology; D011494:Protein Kinases / Q000378:metabolism*; D034741:RNA, Small Interfering / Q000235:genetics; D015398:Signal Transduction / Q000235:genetics; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000494:pharmacology; D058570:TOR Serine-Threonine Kinases; D013964:Thyroid Neoplasms / Q000188:drug therapy* / Q000201:enzymology* / Q000235:genetics / Q000473:pathology; D014162:Transfection; D023041:Xenograft Model Antitumor Assays
chemical_list: D058534:Class I Phosphatidylinositol 3-Kinases; D051058:Oncogene Protein v-akt; D019869:Phosphatidylinositol 3-Kinases; D000081082:Phosphoinositide-3 Kinase Inhibitors; D010767:Phosphorylcholine; D011494:Protein Kinases; D034741:RNA, Small Interfering; D020123:Sirolimus; D058570:TOR Serine-Threonine Kinases; C105905:perifosine; C401859:temsirolimus; C546842:MTOR protein, human; C546843:mTOR protein, mouse; C484760:PIK3CA protein, human
references.citation: J Clin Oncol. 2004 Jul 15;22(14):2954-63
references.pmid: 15254063
references.citation: Cancer Epidemiol Biomarkers Prev. 2009 Mar;18(3):784-91
references.pmid: 19240234
references.citation: J Clin Endocrinol Metab. 2005 Aug;90(8):4688-93
references.pmid: 15928251
references.citation: Proc Natl Acad Sci U S A. 2004 Jul 13;101(28):10380-5
references.pmid: 15240889
references.citation: Clin Cancer Res. 2004 Nov 15;10(22):7450-6
references.pmid: 15569974
references.citation: Cell Signal. 2009 May;21(5):656-64
references.pmid: 19166931
references.citation: Immunol Cell Biol. 2000 Aug;78(4):447-51
references.pmid: 10947872
references.citation: BMC Cancer. 2009 Jan 27;9:34
references.pmid: 19173737
references.citation: Cancer Res. 2005 May 1;65(9):3664-70
references.pmid: 15867361
references.citation: Nat Med. 2008 Dec;14(12):1351-6
references.pmid: 19029981
references.citation: J Clin Endocrinol Metab. 2008 Feb;93(2):611-8
references.pmid: 18000091
references.citation: Cancer. 1998 Dec 15;83(12):2638-48
references.pmid: 9874472
references.citation: Cancer Treat Rev. 2004 Apr;30(2):193-204
references.pmid: 15023437
references.citation: J Clin Endocrinol Metab. 2008 Jan;93(1):278-84
references.pmid: 17989125
references.citation: JAMA. 2006 May 10;295(18):2164-7
references.pmid: 16684987
references.citation: Nat Rev Drug Discov. 2005 Dec;4(12):988-1004
references.pmid: 16341064
references.citation: Endocr Relat Cancer. 2009 Mar;16(1):17-44
references.pmid: 18987168
references.citation: Oncogene. 2008 Sep 18;27(41):5497-510
references.pmid: 18794884
references.citation: Cancer Res. 2005 Nov 15;65(22):10199-207
references.pmid: 16288007
references.citation: J Clin Endocrinol Metab. 2008 Aug;93(8):3106-16
references.pmid: 18492751
references.citation: Endocr Pathol. 2008 Fall;19(3):150-5
references.pmid: 18766471
references.citation: J Clin Oncol. 2008 Oct 10;26(29):4708-13
references.pmid: 18541897
references.citation: Clin Cancer Res. 2007 Dec 15;13(24):7421-31
references.pmid: 18094426
references.citation: Clin Cancer Res. 2007 Feb 15;13(4):1161-70
references.pmid: 17317825
references.citation: Thyroid. 2004 Dec;14(12):1056-60
references.pmid: 15650358
references.citation: Endocrinology. 1997 Jun;138(6):2610-4
references.pmid: 9165055
references.citation: Curr Cancer Drug Targets. 2008 May;8(3):187-98
references.pmid: 18473732
references.citation: Cell Signal. 2002 May;14(5):381-95
references.pmid: 11882383
references.citation: Curr Opin Investig Drugs. 2002 Aug;3(8):1249-53
references.pmid: 12211424
references.citation: Mol Cell Biol. 1999 Jun;19(6):4525-34
references.pmid: 10330191
references.citation: Clin J Oncol Nurs. 2008 Aug;12(4):639-46
references.pmid: 18676330
references.citation: Herz. 1999 May;24(3):189-95
references.pmid: 10412642
references.citation: Hum Mol Genet. 2001 Feb 1;10(3):251-8
references.pmid: 11159944
references.citation: PLoS One. 2008 Aug 26;3(8):e3065
references.pmid: 18725974
references.citation: J Clin Endocrinol Metab. 2008 Nov;93(11):4331-41
references.pmid: 18713817
references.citation: Curr Pharm Des. 2008;14(21):2061-74
references.pmid: 18691116
references.citation: Eur J Cancer. 2002 Aug;38(12):1615-21
references.pmid: 12142051
references.citation: Endocrinol Metab Clin North Am. 2008 Jun;37(2):525-38, xi
references.pmid: 18502341
references.citation: N Engl J Med. 2008 Jul 3;359(1):31-42
references.pmid: 18596272
references.citation: Cancer Res. 2002 Sep 1;62(17):5027-34
references.pmid: 12208757
references.citation: Breast Cancer Res Treat. 2008 Nov;112(2):217-27
references.pmid: 18074223
references.citation: Methods Enzymol. 1994;235:29-39
references.pmid: 8057901
references.citation: Curr Oncol Rep. 2009 Mar;11(2):102-10
references.pmid: 19216841
references.citation: J Clin Oncol. 2008 Oct 10;26(29):4714-9
references.pmid: 18541894
references.citation: Cancer Res. 2001 Aug 15;61(16):6105-11
references.pmid: 11507060
references.citation: J Clin Endocrinol Metab. 2007 Jun;92(6):2387-90
references.pmid: 17426084
references.citation: Otolaryngol Clin North Am. 2008 Dec;41(6):1135-46, ix
references.pmid: 19040974